Search research articles
Contact Us
Filters
Showing results (111-120 of 139) with videos related to
Page
of 14
Sort By:
Nature Communications
|
May 9, 2025
Capivasertib plus fulvestrant in patients with HR-positive/HER2-negative advanced breast cancer: phase 3 CAPItello-291 study extended Chinese cohort
Xichun Hu, Qingyuan Zhang, Tao Sun, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 19, 2026
Exploratory analysis of PTEN deficiency by immunohistochemistry from the Phase III CAPItello-291 trial
Komal Jhaveri, Hope S Rugo, Javier Cortés, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 5, 2024
Phase I/Ib Trial of Inavolisib Plus Palbociclib and Endocrine Therapy for <i>PIK3CA</i>-Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced or Metastatic Breast Cancer
Komal L Jhaveri, Melissa K Accordino, Philippe L Bedard, et al.
The New England Journal of Medicine
|
May 31, 2023
Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer
Nicholas C Turner, Mafalda Oliveira, Sacha J Howell, et al.
The Lancet. Oncology
|
August 30, 2024
Capivasertib and fulvestrant for patients with hormone receptor-positive, HER2-negative advanced breast cancer (CAPItello-291): patient-reported outcomes from a phase 3, randomised, double-blind, placebo-controlled trial
Mafalda Oliveira, Hope S Rugo, Sacha J Howell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 25, 2023
Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
Javier Pascual, Miguel Gil-Gil, Paula Proszek, et al.
Cancer Discovery
|
October 11, 2011
Functional viability profiles of breast cancer
Rachel Brough, Jessica R Frankum, David Sims, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 3, 2023
Phase Ia/b Study of Giredestrant ± Palbociclib and ± Luteinizing Hormone-Releasing Hormone Agonists in Estrogen Receptor-Positive, HER2-Negative, Locally Advanced/Metastatic Breast Cancer
Komal L Jhaveri, Meritxell Bellet, Nicholas C Turner, et al.
Breast Cancer Research and Treatment
|
October 18, 2024
Longitudinal monitoring of circulating tumor DNA to detect relapse early and predict outcome in early breast cancer
Isaac Garcia-Murillas, Rosalind J Cutts, Giselle Walsh-Crestani, et al.
Nature Communications
|
April 24, 2021
Genomic profile of advanced breast cancer in circulating tumour DNA
Belinda Kingston, Rosalind J Cutts, Hannah Bye, et al.
Page
of 14
Search research articles
Search
Showing results (111-120 of 139) with videos related to
Sort By:
Page
of 14
Nature Communications
|
May 9, 2025
Capivasertib plus fulvestrant in patients with HR-positive/HER2-negative advanced breast cancer: phase 3 CAPItello-291 study extended Chinese cohort
Xichun Hu, Qingyuan Zhang, Tao Sun, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 19, 2026
Exploratory analysis of PTEN deficiency by immunohistochemistry from the Phase III CAPItello-291 trial
Komal Jhaveri, Hope S Rugo, Javier Cortés, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 5, 2024
Phase I/Ib Trial of Inavolisib Plus Palbociclib and Endocrine Therapy for <i>PIK3CA</i>-Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced or Metastatic Breast Cancer
Komal L Jhaveri, Melissa K Accordino, Philippe L Bedard, et al.
The New England Journal of Medicine
|
May 31, 2023
Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer
Nicholas C Turner, Mafalda Oliveira, Sacha J Howell, et al.
The Lancet. Oncology
|
August 30, 2024
Capivasertib and fulvestrant for patients with hormone receptor-positive, HER2-negative advanced breast cancer (CAPItello-291): patient-reported outcomes from a phase 3, randomised, double-blind, placebo-controlled trial
Mafalda Oliveira, Hope S Rugo, Sacha J Howell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 25, 2023
Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
Javier Pascual, Miguel Gil-Gil, Paula Proszek, et al.
Cancer Discovery
|
October 11, 2011
Functional viability profiles of breast cancer
Rachel Brough, Jessica R Frankum, David Sims, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 3, 2023
Phase Ia/b Study of Giredestrant ± Palbociclib and ± Luteinizing Hormone-Releasing Hormone Agonists in Estrogen Receptor-Positive, HER2-Negative, Locally Advanced/Metastatic Breast Cancer
Komal L Jhaveri, Meritxell Bellet, Nicholas C Turner, et al.
Breast Cancer Research and Treatment
|
October 18, 2024
Longitudinal monitoring of circulating tumor DNA to detect relapse early and predict outcome in early breast cancer
Isaac Garcia-Murillas, Rosalind J Cutts, Giselle Walsh-Crestani, et al.
Nature Communications
|
April 24, 2021
Genomic profile of advanced breast cancer in circulating tumour DNA
Belinda Kingston, Rosalind J Cutts, Hannah Bye, et al.
Page
of 14